The board has continued to work to find solutions to strengthen the company's financial position in both the short and long term. This work has not yet yielded any results and no decision regarding the company's appeal against the rejection to its application in the EIC accelerator has been received. The board continues this work with undiminished vigour.
Currently, the company's working capital is estimated to last through
The company is listed on the Nasdaq First North Growth Market.
This information is information that
For more information, please contact:
Email: patrik.sundh@clinescientific.com
Phone: +46 0703585088
Pepparedsleden 1
AstraZeneca BioVentureHub Email: info@clinescientific.com
431 53 MÖLNDAL Website: www.clinescientific.com
About
https://news.cision.com/cline/r/cline-scientific-provides-an-update-on-the-company-s-financial-position,c3970658
https://mb.cision.com/Main/12114/3970658/2770015.pdf
(c) 2024 Cision. All rights reserved., source